Malignant growth informatics and accuracy medication organization Tempus said today that it has landed $200 million out of a Series F speculation around. This new round brings the four-year-old company’s absolute funding to $520 million and valuation to $3.1 billion.
The organization reported the financing round on Thursday, alongside designs to extend its clinical information to enable doctors to treat more maladies. Tempus will run a test case program to help patients determined to have melancholy and diabetes next.
Tempus has assembled a library of clinical information close by a working framework to make the information valuable for clinicians and analysts alike. The organization utilizes AI, cutting edge sequencing, and computerized reasoning helped picture acknowledgment to empower logical revelation and help doctors settle on continuous choices to manage the treatment of their patients.
Established in 2015, Tempus is clinical information that consolidates AI, quality sequencing and AI-helped picture acknowledgment to furnish doctors with experiences. Doctors are then ready to utilize that information to customize treatment plans for individual patients, in light of their quality profiles and other significant information. Tempus additionally has a sequencing research center in its rambling Chicago central station.
Tempus CEO and Founder Eric Lefkofsky told GenomeWeb late last year that the company was starting to move into diabetes sectors.
I believe the same [issues] will exist in cardiovascular disease, neurological disorders, infectious disease, and endocrinology. – Eric Lefkofsky, Tempus CEO and Founder
“From our founding, Tempus has been singularly focused on improving the lives of patients diagnosed with the disease, starting with cancer,” Lefkofsky said in a new statement today. “Three and a half years later, we are empowering stakeholders across healthcare with insights derived from real-world clinical evidence connected to rich molecular data.”